DongKoo Bio & Pharma Balance Sheet Health
Financial Health criteria checks 3/6
DongKoo Bio & Pharma has a total shareholder equity of ₩112.6B and total debt of ₩67.8B, which brings its debt-to-equity ratio to 60.2%. Its total assets and total liabilities are ₩225.6B and ₩113.1B respectively. DongKoo Bio & Pharma's EBIT is ₩13.5B making its interest coverage ratio 7.3. It has cash and short-term investments of ₩23.5B.
Key information
60.2%
Debt to equity ratio
₩67.79b
Debt
| Interest coverage ratio | 7.3x |
| Cash | ₩23.50b |
| Equity | ₩112.57b |
| Total liabilities | ₩113.07b |
| Total assets | ₩225.64b |
Recent financial health updates
No updates
Recent updates
More Unpleasant Surprises Could Be In Store For DongKoo Bio & Pharma Co., Ltd.'s (KOSDAQ:006620) Shares After Tumbling 32%
Aug 23
Should You Be Adding DongKoo Bio & Pharma (KOSDAQ:006620) To Your Watchlist Today?
Jul 25We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings
Mar 27Financial Position Analysis
Short Term Liabilities: A006620's short term assets (₩91.7B) do not cover its short term liabilities (₩98.4B).
Long Term Liabilities: A006620's short term assets (₩91.7B) exceed its long term liabilities (₩14.6B).
Debt to Equity History and Analysis
Debt Level: A006620's net debt to equity ratio (39.4%) is considered satisfactory.
Reducing Debt: A006620's debt to equity ratio has increased from 29.3% to 60.2% over the past 5 years.
Debt Coverage: A006620's debt is not well covered by operating cash flow (17.3%).
Interest Coverage: A006620's interest payments on its debt are well covered by EBIT (7.3x coverage).